PTK2 and ovarian carcinoma: Although integrin inhibitors as monotherapy agents have failed to demonstrate benefits in metastatic ovarian tumors, possibly due to compensation by other integrins [36], simultaneous targeting of integrin-FAK and c-Myc signaling has been found to synergistically disrupt tumor cell proliferation and survival in HGS-OvCa [37], supporting the notion of combinatorial targeting of integrin as a valid approach for treating ovarian cancer, particularly that of mesenchymal subtype.